LDHC and breast carcinoma: To conclude, we believe that developing LDHC‐specific therapeutic interventions using specific chemical inhibitors or siRNA delivery approaches presents an attractive paradigm to enhance the efficacy of current drugs and to improve clinical outcome in breast cancer.